Article
Medicine, General & Internal
Yin Tao, Xue-Ting Tang, Xing Li, An-Shan Wu, Hou-Shen Zhou, Cheng-fang Zhou
Summary: This study evaluated the role of neoadjuvant chemotherapy (NACT) with intraperitoneal perfusion of bevacizumab in advanced ovarian cancer. The results showed that treatment with the TCB regimen significantly reduced serum levels of CA125 and ascites volume, as well as intraoperative blood loss and operation time. Patients treated with the TCB regimen had a higher surgical satisfaction rate, and a lower incidence of postoperative complications compared with the TC group. No severe complications were observed between the two groups during chemotherapy.
FRONTIERS IN MEDICINE
(2022)
Article
Oncology
Shinichi Tate, Kyoko Nishikimi, Ayumu Matsuoka, Satoyo Otsuka, Makio Shozu
Summary: The study evaluated the safety and efficacy of weekly paclitaxel and cisplatin chemotherapy in patients with ovarian cancer who developed carboplatin hypersensitivity reaction. The majority of patients were able to complete the treatment without hypersensitivity reactions, and the therapy was found to be well-tolerated and effective for most patients.
Article
Medicine, Research & Experimental
Xiangbin Tan, Shuangyou Zou, Hui Chen, Dachao Chen
Summary: This study compared the efficacy of paclitaxel liposomes combined with carboplatin and paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer. The results showed that paclitaxel liposomes combined with carboplatin had a higher overall response rate and could reduce serum marker levels and the occurrence of adverse reactions.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
(2023)
Article
Oncology
Claire Falandry, Frederique Rousseau, Marie-Ange Mouret-Reynier, Fabien Tinquaut, Domenica Lorusso, Jorn Herrstedt, Aude-Marie Savoye, Laetitia Stefani, Emmanuelle Bourbouloux, Robert Sverdlin, Veronique D'Hondt, Alain Lortholary, Pierre-Emmanuel Brachet, Alain Zannetti, Emmanuelle Malaurie, Laurence Venat-Bouvet, Olivier Tredan, Loic Mourey, Eric Pujade-Lauraine, Gilles Freyer
Summary: This study conducted a randomized clinical trial for vulnerable older patients with ovarian cancer, and found that single-agent carboplatin was less effective with significantly worse survival outcomes compared to every-3-weeks or weekly carboplatin-paclitaxel regimens.
Article
Oncology
Maria Rubinstein, Sherry Shen, Bradley J. Monk, David S. P. Tan, Angelica Nogueira-Rodrigues, Daisuke Aoki, Jalid Sehouli, Vicky Makker
Summary: Incidence and mortality of endometrial cancer are increasing among all ethnic groups. Carboplatin plus paclitaxel is the frontline treatment, but subsequent traditional cytotoxic chemotherapy is challenging. Molecular characterization has led to the development of precision immunotherapies and targeted therapies. The applicability of platinum rechallenge is subjective and limited by small retrospective studies.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
G. E. Konecny, A. E. Wahner Hendrickson, T. M. Davidson, B. J. Winterhoff, S. Ma, S. Mahner, J. Sehouli, P. A. Fasching, G. Feisel-Schwickardi, M. Poelcher, L. D. Roman, A. Rody, B. Y. Karlan, S. A. Mullany, H. Chen, I. L. Ray-Coquard, D. M. Provencher, A. Yachnin, P. H. Cottu, J. A. Glaspy, P. Haluska, D. J. Slamon
Summary: This study investigated the efficacy and safety of adding ganitumab to CP chemotherapy in primary EOC patients, but did not show improvement in PFS. The results do not support further study of ganitumab in unselected EOC patients.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
David H. Johnson, Louis Fehrenbacher, William F. Novotny, Roy S. Herbst, John J. Nemunaitis, David M. Jablons, Corey J. Langer, Russell F. DeVore III, Jacques Gaudreault, Lisa A. Damico, Eric Holmgren, Fairooz Kabbinavar
Summary: This study aimed to investigate the efficacy and safety of bevacizumab in combination with carboplatin and paclitaxel for advanced or recurrent non-small-cell lung cancer. The results showed that the addition of bevacizumab improved overall response and time to progression, but bleeding was the most prominent adverse event. Patients with nonsquamous cell histology appeared to have better treatment outcomes and acceptable safety risks.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Immunology
Maojin You, Xiaoling Zeng, Jinrong Zhang, Yufan Huang, Yalan Zhang, Zhongjie Cai, Yingying Hu
Summary: This study evaluated the cost-effectiveness of DOS-CP compared to PLB-CP as a first-line treatment for advanced EC. The findings suggest that DOS-CP is unlikely to be a cost-effective treatment option from the perspective of the Chinese healthcare system.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Sandro Pignata, Giovanni Scambia, Clorinda Schettino, Laura Arenare, Carmela Pisano, Davide Lombardi, Ugo De Giorgi, Claudia Andreetta, Saverio Cinieri, Carmine De Angelis, Domenico Priolo, Claudia Casanova, Marta Rosati, Filippo Greco, Elena Zafarana, Ilaria Schiavetto, Serafina Mammoliti, Sabrina Chiara Cecere, Vanda Salutari, Simona Scalone, Alberto Farolfi, Marilena Di Napoli, Domenica Lorusso, Piera Gargiulo, Daniela Califano, Daniela Russo, Anna Spina, Rossella De Cecio, Paolo Chiodini, Francesco Perrone
Summary: This study compared carboplatin and paclitaxel with avelumab plus carboplatin and paclitaxel as first-line treatment in patients with advanced or recurrent endometrial cancer. The addition of avelumab showed potential for improving progression-free survival, but further investigation is needed.
Article
Oncology
Corey J. Langer, Ajeet Gajra, Cesare Gridelli, Kartik Konduri, Daniel Morgensztern, David Spigel, Denis Talbot, Michael Thomas, Jared Weiss, Richard Pilot, Rafia Bhore, Marianne Wolfsteiner, Teng Jin Ong, Mark Socinski
Summary: Despite the underrepresentation of certain patient populations in clinical trials for advanced NSCLC, a pooled analysis of elderly patients and those with renal impairment, diabetes, or poor performance status showed varying but promising outcomes, supporting the use of nab-paclitaxel-based regimens in these historically understudied and vulnerable populations.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Simona Frezzini, Germana Tognon, Grazia Artioli, Angiolo Gadducci, Rossella Lauria, Annamaria Ferrero, Saverio Cinieri, Andrea De Censi, Enrico Breda, Paolo Scollo, Ugo De Giorgi, Andrea Alberto Lissoni, Dionyssios Katsaros, Domenica Lorusso, Vanda Salutari, Sabrina Chiara Cecere, Eleonora Zaccarelli, Margherita Nardin, Giorgio Bogani, Mariagrazia Distefano, Stefano Greggi, Maria Carmela Piccirillo, Roldano Fossati, Gaia Giannone, Laura Arenare, Ciro Gallo, Francesco Perrone, Sandro Pignata
Summary: The study investigated the clinical and biological prognostic factors for advanced ovarian cancer patients receiving first-line treatment with carboplatin, paclitaxel, and bevacizumab. Results showed that the progression-free survival and overall survival were 20.8 months and 41.1 months, respectively. Clinical factors such as performance status, stage, and residual disease after primary surgery were significant predictors of survival outcomes.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2021)
Article
Oncology
Tamar Safra, Barliz Waissengrin, Talya Levy, Ellie Leidner, Rotem Merose, Diana Matceyevsky, Dan Grisaru, Ido Laskov, Nadav Mishaan, Rotem Shayzaf, Ido Wolf
Summary: The study compared the efficacy and safety of the traditional PC-3W regimen with the modified PC-W regimen for ovarian cancer treatment, finding that PC-W had better median progression-free survival and overall survival compared to PC-3W, with fewer adverse effects. It showed a better safety profile, particularly suitable for elderly or frail patients.
Article
Otorhinolaryngology
James Han, Kaveh Zakeri, Gabriel Raab, Jennifer Hesse, Achraf Shamseddine, Linda Chen, Yao Yu, Jung Julie Kang, Sean M. M. McBride, Nadeem Riaz, C. Jillian Tsai, Daphna Gelblum, Eric J. J. Sherman, Richard J. J. Wong, Loren Michel, Nancy Y. Y. Lee
Summary: This study reports the outcomes of cisplatin-ineligible HNSCC patients treated with definitive chemoradiation using carboplatin and paclitaxel. The results show that chemoradiation with carboplatin and paclitaxel is an effective treatment option for controlling locoregional recurrences and distant metastases, and improving progression-free survival and overall survival in these patients.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2023)
Article
Obstetrics & Gynecology
Roy Kessous, Emad Matanes, Ido Laskov, Tamar Wainstock, Jeremie Abitbol, Amber Yasmeen, Shannon Salvador, Susie Lau, Walter H. Gotlieb
Summary: The study showed that patients with advanced ovarian cancer who received dose-dense weekly paclitaxel had significantly better progression-free survival compared to those who received standard 3-weekly chemotherapy. Although the overall survival was also better in the dose-dense group, the difference was not statistically significant. The dose-dense protocol was associated with higher rates of side effects but may be considered as a treatment alternative for advanced ovarian cancer patients.
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
(2021)
Article
Oncology
Maria M. Rubinstein, Rachel N. Grisham, Karen Cadoo, Chrisann Kyi, William P. Tew, Claire F. Friedman, Roisin E. O'Cearbhaill, Dmitriy Zamarin, Qin Zhou, Alexia Iasonos, Ines Nikolovski, Hongmei Xu, Krysten N. Soldan, Imogen Caird, Madhuri Martin, Joyce Guillen, Khalil T. Eid, Carol Aghajanian, Vicky Makker
Summary: The study evaluated the safety and tolerability of combination therapy with Selinexor and CP in advanced ovarian and endometrial cancers, showing promising efficacy. The most common treatment-related adverse events included thrombocytopenia, leukopenia, and hyperglycemia.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Joren Vanbraband, Nancy Van Damme, Gauthier Bouche, Geert Silversmit, Anke De Geyndt, Eric de Jonge, Gerd Jacomen, Frederic Goffin, Hannelore Denys, Frederic Amant
Summary: This study assesses the completeness and selection bias of the EFFECT database, finding bias in both the participating hospitals and the patients included. However, the EFFECT database provides detailed information on the real-world clinical care of corpus uteri cancer in Belgium, making it an important tool for measuring and improving patient care quality.
Article
Pharmacology & Pharmacy
David Damoiseaux, Silvia Calpe, Hilde Rosing, Jos H. Beijnen, Alwin D. R. Huitema, Christianne Lok, Thomas P. C. Dorlo, Frederic Amant
Summary: Little is known about the safety of chemotherapy during breastfeeding for infants. This study aimed to provide insight into the presence of chemotherapy drugs in breast milk to help clinicians make informed decisions. The results showed that for some chemotherapy drugs, it may be safe to breastfeed 1-3 days after administration to avoid high cumulative drug doses.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Oncology
Klaudia Zak, Bartlomiej Zaremba, Alicja Rajtak, Jan Kotarski, Frederic Amant, Marcin Bobinski
Summary: Uterine sarcomas are the second most common unexpected malignancy diagnosed after surgery. Using multiple parameters in specific diagnostic scales and applying machine learning models and artificial intelligence can help differentiate uterine leiomyosarcomas (ULMS) and uterine leiomyomas (ULM) preoperatively. Establishing multicenter databases is necessary for collecting a large number of ULMS patients.
Article
Oncology
Emiel A. De Jaeghere, Sandra Tuyaerts, An M. T. Van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens, Peter Vuylsteke, Stephanie Henry, Xuan Bich Trinh, Peter A. van Dam, Sandrine Aspeslagh, Alex De Caluwe, Eline Naert, Diether Lambrechts, An Hendrix, Olivier De Wever, Koen K. Van de Vijver, Frederic Amant, Katrien Vandecasteele, Hannelore G. Denys
Summary: The PRIMMO study conducted a phase II trial on patients with pretreated persistent/recurrent/metastatic cervical or endometrial cancer. The study found that pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail had modest but durable antitumor activity, with acceptable but not negligible toxicity.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Medical Laboratory Technology
Huiwen Che, Tatjana Jatsenko, Liesbeth Lenaerts, Luc Dehaspe, Leen Vancoillie, Nathalie Brison, Ilse Parijs, Kris Van den Bogaert, Daniela Fischerova, Ruben Heremans, Chiara Landolfo, Antonia Carla Testa, Adriaan Vanderstichele, Lore Liekens, Valentina Pomella, Agnieszka Wozniak, Christophe Dooms, Els Wauters, Sigrid Hatse, Kevin Punie, Patrick Neven, Hans Wildiers, Sabine Tejpar, Diether Lambrechts, An Coosemans, Dirk Timmerman, Peter Vandenberghe, Frederic Amant, Joris Robert Vermeesch
Summary: This study demonstrates the potential of using cfDNA analysis for non-invasive cancer detection and typing. The researchers identified cfDNA signatures that accurately discriminated between different types of cancers and healthy controls. This approach provides a generic analytical strategy for pan-cancer detection.
CLINICAL CHEMISTRY
(2022)
Review
Oncology
Linda Nooij, Eva Schaake, Anna Reyners, Henry Zijlmans, Frederic Amant
Summary: Researches on treatment options for patients with locally advanced vulvar cancer (LAVC) are rare, and there is a lack of high-level evidence for a primary treatment choice. Moreover, current treatment options are associated with considerable morbidity and complications. More effective treatment options are urgently needed. This review explores current treatment possibilities, focusing on literature regarding neoadjuvant chemotherapy (NACT) followed by surgery. Despite limited and heterogeneous data, NACT followed by surgery may be an effective and well-tolerated treatment alternative with lower morbidity compared with current treatment options.
CURRENT OPINION IN ONCOLOGY
(2022)
Review
Surgery
Maurits Lange, J. Joris Hage, Refaat B. Karim, Frederic Amant
Summary: Various techniques have been introduced for reduction labiaplasty, but there is no single technique that is optimal for every patient. The choice of technique should be based on anatomical, configurational, and technical considerations, as well as the patient's personal preferences. An algorithm has been developed to guide the choice of technique, considering factors such as resection or retention of the labial free rim, required labial width reduction, labial vascular status, prevention of iatrogenic labial thickening, and preservation of labial sensibility. The choice of techniques includes edge trimming, central spindle form de-epithelialization or full-thickness resection, and modifications of the wedge resection or de-epithelialization technique.
ARCHIVES OF PLASTIC SURGERY-APS
(2023)
Article
Environmental Sciences
Ilana Struys, Eline Verscheure, Liesbeth Lenaerts, Frederic Amant, Lode Godderis, Manosij Ghosh
Summary: Due to the genotoxic consequences of antineoplastic agents on non-cancerous tissue, it is crucial to understand their effects. This study aimed to characterize the genotoxic profile of different classes of antineoplastic drugs using a cell line assay. The results showed increased micronucleus formation with all tested drugs, as well as specific abnormalities for each drug class. These findings can aid in interpreting genotoxic aberrations in patients treated with these drugs.
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
(2023)
Article
Oncology
Pien Lof, Ellen G. Engelhardt, Mignon D. J. M. van Gent, Constantijne H. Mom, Fleur M. F. Rosier-van Dunne, W. Marchien van Baal, Harold R. Verhoeve, Brenda B. J. Hermsen, Marjolijn B. Verbruggen, Majoie Hemelaar, Jojanneke M. G. van de Swaluw, Haye C. Knipscheer, Judith A. F. Huirne, Steven M. Westenberg, Willemien J. van Driel, Eveline M. A. Bleiker, Frederic Amant, Christianne A. R. Lok
Summary: This study evaluated cancer-specific distress and treatment satisfaction in patients with an ovarian mass. It found that many patients experienced high cancer-specific distress during the work-up process. However, patients were generally satisfied with their treatment regardless of the diagnosis and treatment location. This suggests that patients' preferences should be considered when developing risk assessment strategies.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Review
Oncology
Fabian De Smedt, Frederique Dessy, Luciano Carestia, Pamela Baldin, Frank Aboubakar Nana, Philippe Clapuyt, Veronique Boon, Frederic Amant, Mina Mhallem Gziri
Summary: Oncogenic rearrangements in the ALK gene are responsible for 5% of NSCLC cases, and ALK inhibitors have significantly improved the outcomes in ALK(+) mNSCLC patients. ALK(+) NSCLC accounts for 38% of cases in women of childbearing age, presenting new challenges in lung cancer and obstetrics research. This study reported a case of a pregnant HIV-infected patient with ALK(+) mNSCLC who had no fetal developmental abnormalities or obstetric complications during treatment with alectinib.
Article
Orthopedics
Maurits Lange, J. Joris Hage, Arend Aalbers, Esther M. K. Wit, Frederic Amant, Marije J. Hoornweg
Summary: Primary intra- or transabdominal transplantation of extended rectus abdominis myocutaneous (ERAM) flap can prevent surgical complications. Delaying the flap can reduce the risk of intra-abdominal flap loss. However, it may lead to other complications.
JOURNAL OF PLASTIC SURGERY AND HAND SURGERY
(2023)
Article
Pharmacology & Pharmacy
David Damoiseaux, Daniel Centanni, Jos H. Beijnen, Frederic Amant, Alwin D. R. Huitema, Thomas P. C. Dorlo
Summary: Information on the distribution of chemotherapeutic drugs to breast milk is limited, and our study aimed to predict chemotherapy distribution in a more realistic breastfeeding population and evaluate the effect of discarding breast milk on potential chemotherapy exposure in infants.
CLINICAL PHARMACOKINETICS
(2023)
Article
Oncology
Jenneke C. Kasius, Rita Trozzi, Johanna Pijnenborg, Thais Baert, Annouschka Laenen, Anne-Sophie Van Rompuy, Ignacio Zapardiel, Giuseppe Vizzielli, Jure Knez, Francesco Fanfani, Frederic Amant
Summary: The study aims to determine the association between molecular classification and disease stage in endometrial cancer, in order to guide surgical approach. 1000 female patients aged 18 or above will be enrolled, and results on staging and oncological outcomes are expected in 2027 and 2029 respectively.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Oncology
Sander Dumont, Vincent Vandecaveye, Raphaela Carmen Dresen, Els Van Nieuwenhuysen, Thais Baert, Frederic Amant, Valerie Broeckhoven, Toon Van Gorp
Summary: This study aimed to evaluate the diagnostic value of whole-body diffusion-weighted magnetic resonance imaging (WB-DWI/MRI) in predicting resectable disease during secondary cytoreductive surgery for relapsed epithelial ovarian cancer. The study found that WB-DWI/MRI accurately predicted resectable disease and was associated with improved progression-free and overall survival of the patients.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Obstetrics & Gynecology
Teska Schuurman, Ji-Ying Song, Vera Wolters, Marieke van de Ven, Nienke van Trommel, Ina Beerendonk, Frederic Amant, Christianne Lok
Summary: This study found that chemotherapy can cause damage to the maternal ovaries during pregnancy, and the extent of this damage depends on the type of chemotherapy and the duration of exposure. Short-term exposure leads to more severe damage, but it might be temporary. Chemotherapy also results in the loss of primordial follicles and DNA damage, with paclitaxel causing the least damage.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
(2023)